Human pluripotent stem cell (hPSC)-based therapies offer promise but pose potential risks due to culture-acquired genetic variants, some of which have been linked with cancer. An international workshop addressed these concerns, highlighting the need for improved strategies to stratify variants and chart a path toward definitive guidelines in hPSC-based therapy.
BENVENISTY Nissim;
DRAPER Jonathan;
GOKHALE Paul J.;
HEALY Lyn;
HEWITT Zoe;
HURSH Deborah;
HODGSON Adam;
LUDWIG Tenneille;
MAH Nancy;
MCCLELLAND Sarah;
MENNECOZZI Milena;
MERKLE Florian;
MOUNTFORD Joanne;
PERA Martin;
PRIGIONE Alessandro;
RODRIGUEZ Tristan A.;
ROSSI Andrea;
ROUHANI Foad;
SAEB-PARSY Kourosh;
SELFA ASPIROZ Lucia;
SHAKIBA Nika;
SPITS Claudia;
TONGE Peter;
BARBARIC Ivana;
2025-07-11
CELL PRESS
JRC139586
1875-9777 (online),
https://doi.org/10.1016/j.stem.2025.03.003,
https://publications.jrc.ec.europa.eu/repository/handle/JRC139586,
10.1016/j.stem.2025.03.003 (online),
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Additional supporting files
| File name | Description | File type | |
|---|
